ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction (MI) and preserved left ventricular ejection fraction (LVEF) found this ...

– Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors – – Supplemental New Drug ...

One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...

In the dynamic world of clinical trials, innovative methods are vital to improving the efficiency and reliability of medical research. One area that has garnered both interest and scepticism is ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...

Exelixis, Inc., a globally ambitious oncology company, announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumours (epNET) ...

Author(s)Goadsby PJ, Reuter U, Hallstr&#246, m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377(22):2123-2132. doi: 10.1056/NEJMoa1705848. Certain medications ...